EyePoint Pharmaceuticals Set to Highlight Innovations at Conferences
EyePoint Pharmaceuticals Participates in Key Conferences
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), known for its commitment to developing groundbreaking therapeutics, recently announced its participation in various significant investor conferences. The management team is eager to share insights about their innovative work, especially in the realm of retinal diseases, during these crucial events.
Upcoming Conference Schedule
EyePoint's management will be taking part in the following conferences, showcasing their latest advancements and discussions around their innovative treatments:
Citi's BioPharma Conference
Forum: Fireside Chat
Date: September 2, 2025
Time: 2:30 p.m. ET
Cantor Global Healthcare Conference
Forum: Fireside Chat
Date: September 3, 2025
Time: 2:45 p.m. ET
Morgan Stanley Annual Healthcare Conference
Forum: 1x1 Investor Meetings
Date: September 9, 2025
Webcast Availability
For those interested in following the presentations, a live webcast will be available along with an archived replay. This can be accessed via the Investors section of EyePoint's official website.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical enterprise dedicated to transforming the lives of patients suffering from severe retinal diseases. The company's leading product candidate, DURAVYU™, represents a significant advancement in the treatment of VEGF-mediated retinal conditions. Utilizing next-generation bioerodible Durasert E™ technology, DURAVYU is designed to sustain treatment delivery and improve patient outcomes.
Currently, DURAVYU is the subject of two Phase 3 pivotal trials aimed at treating wet age-related macular degeneration (wet AMD), with topline results expected in 2026. It also recently completed a successful Phase 2 trial for diabetic macular edema (DME), initiating planning for its Phase 3 trials.
Innovation and Community Commitment
EyePoint is devoted to engaging with the retina community to enhance the quality of life for patients. With four approved medications over three decades, the company proudly reflects on its history of treating tens of thousands of eyes through its innovative approaches.
Location and Licensing Information
Headquartered in Watertown, Massachusetts, EyePoint houses a commercial manufacturing facility in nearby Northbridge. Importantly, vorolanib has been exclusively licensed to EyePoint by Equinox Sciences for localized treatment of ophthalmic diseases, expanding its reach beyond certain territories in Asia.
DURAVYU has also received conditional FDA acceptance as the proprietary name for EYP-1901. While it is known that DURAVYU is still under investigation and yet to receive FDA approval, the timeline for potential approval remains uncertain.
Contact Information
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
Email: tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
Email: aphillips@greenroompr.com
Frequently Asked Questions
What is EyePoint Pharmaceuticals focused on?
EyePoint Pharmaceuticals is dedicated to developing innovative therapeutic solutions for serious retinal diseases.
What notable conferences is EyePoint participating in?
EyePoint will participate in Citi's BioPharma Conference, the Cantor Global Healthcare Conference, and the Morgan Stanley Annual Healthcare Conference.
What is DURAVYU?
DURAVYU is an investigational treatment for retinal diseases, designed for sustained delivery using advanced technology.
Where is EyePoint Pharmaceuticals located?
EyePoint is headquartered in Watertown, Massachusetts, with a manufacturing facility in Northbridge.
Who should I contact for more information?
For investor inquiries, contact Tanner Kaufman or Jenni Lu at FTI Consulting; for media inquiries, reach out to Amy Phillips at Green Room Communications.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.